Navigation Links
Cepheid Reports Fourth Quarter and Full Year 2010 Results

SUNNYVALE, Calif., Jan. 27, 2011 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today reported revenue for the fourth quarter of 2010 of $58.7 million.  Net income was $1.3 million, or $0.02 per fully diluted share, which compares to revenue of $49.2 million and a net loss of $4.3 million, or $(0.07) per share, in the fourth quarter of fiscal 2009.  Excluding amortization of purchased intangible assets and stock compensation expenses, non-GAAP net income for the fourth quarter of fiscal 2010 was $6.1 million, or $0.09 per fully diluted share.  This compares to a non-GAAP net income of $0.3 million, or $0.01 per fully diluted share, in the fourth quarter of fiscal 2009.

Fiscal 2010 OverviewFor the full fiscal year ended December 31, 2010, Cepheid reported revenue of $212.5 million which compares to revenue of $170.6 million in 2009.  Net loss for the full year was $5.9 million, or $(0.10) per share, which compares to a net loss of $22.5 million, or $(0.39) per share, in 2009.  Excluding amortization of purchased intangible assets and stock compensation expenses, non-GAAP net income for the full year was $12.5 million, or $0.20 per fully diluted share.  This compares to a non-GAAP net loss, which excludes amortization of purchased intangible assets, stock compensation expenses and restructuring expenses, of $5.0 million, or $(0.09) per share, for the full year 2009.

"As we enter 2011, awareness of Cepheid's technology leadership and the unique capabilities of our GeneXpert® system has never been higher, with more than 1,800 systems placed globally and our broadest test menu ever," said John Bishop, Cepheid's Chief Executive Officer.  "Strong market adoption of our growing Xpert® test menu was a significant driver for our success in 2010 and is expected to continue in 2011."

Operational Overview

  • Fourth quarter of fiscal 2010 Clinical sales of $46.4 million grew 30% from $35.6 million in the fourth quarter of 2009, and total fourth quarter of fiscal 2010 product sales of $56.2 million grew 17% from the same quarter a year ago.  For the full year 2010, total Clinical sales of $162.5 million grew 40% from $115.9 million reported for the full year 2009.  By industry, product sales were, in millions:

  • Three Months Ended December 31,Full Year Ended December 31,20102009Change20102009ChangeClinical Systems

    $   9.6$ 10.0-4%$   31.3$   26.219%Clinical Reagents

    36.825.644%131.289.746%Total Clinical 46.435.630%162.5115.940%Industrial



    1.01.4-29%4.15.3-23%Total Product Sales$ 56.2$ 48.217%$ 206.9$ 165.225%

  • By geography, product sales were, in millions:

  • Three Months Ended December 31,Full Year Ended December 31,20102009Change20102009ChangeNorth AmericaClinical

    $ 35.8$ 27.132%$ 127.3$   88.544%Other

    8.19.1-11%37.440.3-7%Total North America43.936.221%164.7128.828%InternationalClinical


    1.73.5-51%7.09.0-22%Total International12.312.03%42.236.416%Total Product Sales$ 56.2$ 48.217%$ 206.9$ 165.225%

  • During the fourth quarter of fiscal 2010, Cepheid placed a total of 130 GeneXpert systems and 793 modules.  For the full year 2010, 485 GeneXpert systems and 2,614 modules were installed.  As of December 31, 2010, a cumulative total of 1,860 GeneXpert systems and 10,167 modules have been placed worldwide.
  • Cash and cash equivalents were $79.5 million as of December 31, 2010.
  • DSO was 43 days.

  • Business OutlookFor the fiscal year ending December 31, 2011, the Company expects:

  • Total revenue to be in the range of $245 to $255 million;
  • Net income ranging from a loss of $(0.01) to net income of $0.04 per share;  
  • Non-GAAP net income in the range of $0.30 to $0.35 per share.  

  • Expected non-GAAP net income excludes approximately $18.5 million related to stock compensation expense and approximately $2 million related to the amortization of acquired intangibles.  The fully diluted share count for the year is expected to be approximately 66 million and basic share count is expected to be approximately 61 million.

    Accessing Cepheid's Fourth Quarter and Full Year 2010 Results Conference CallThe company will host a management presentation at 2 p.m. Pacific Time on Thursday, January 27, 2011, to discuss the results.  To access the live webcast, please visit Cepheid's website at at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software.  A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

    Interested participants and investors may also listen to the live teleconference call by dialing (866) 770-7146 or (617) 213-8068, and entering participant code 12255941.  A replay will be available for seven days beginning at 4 p.m. Pacific Time.  Access numbers for this replay are (888) 286-8010 or (617) 801-6888, with passcode 33375156.

    About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit

    Use of Non-GAAP MeasuresThe company has supplemented its reported GAAP financial information with non-GAAP measures that do not include employee share-based compensation expense and amortization of purchased intangible assets and restructuring charges.  The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with GAAP.   The company's management uses the non-GAAP information internally to evaluate its ongoing business, continuing operational performance and cash requirements, and believes these non-GAAP measures are useful to investors as they provide a basis for evaluating the company's cash requirements and additional insight into the underlying operating results and the company's ongoing performance in the ordinary course of its operations.

    These non-GAAP measures may be different from non-GAAP measures used by other companies.  In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.  The company believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with its results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate the company's results of operations in conjunction with the corresponding GAAP measures.

    As described above, the company excludes the following items from one or more of its non-GAAP measures when applicable:

    Employee stock-based compensation expense. These expenses consist primarily of expenses for employee stock options and employee restricted stock under ASC 718 (formerly SFAS 123(R)).  The company excludes employee stock-based compensation expenses from its non-GAAP measures primarily because they are non-cash expenses that the company does not believe are reflective of ongoing operating results.  Further, as the company applies ASC 718, it believes that it is useful to investors to understand the impact of the application of ASC 718 on its results of operations.

    Amortization of purchased intangible assets.  The company incurs amortization of purchased intangible assets in connection with acquisitions.  The company excludes these items because these expenses are not reflective of ongoing operating results in the period incurred.  These amounts arise from the company's prior acquisitions and have no direct correlation to the operation of the company's business.

    Forward-Looking StatementsThis press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to potential growth particularly in the clinical market, demand for certain products, future revenues and future net income/loss, including on a non-GAAP basis. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our success in increasing direct sales and the effectiveness of new sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites; changes in the protocols or levels of testing for Healthcare Associated Infections (HAIs); the company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; unforeseen development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; the impact of competitive products and pricing; the company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.

    All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.

    December 31,Year Ended
    December 31,2010200920102009Revenues:System sales

    $   13,200$   15,545$   46,416$
    42,993Reagent and disposable sales

    42,96932,694160,460122,192Total product sales

    56,16948,239206,876165,185Other revenues

    2,5579655,5925,442Total revenues

    58,72649,204212,468170,627Costs and operating expenses:Cost of product sales

    26,57027,837105,13595,542Collaboration profit sharing

    1,0931,6536,8068,200Research and development

    11,6669,91642,50339,313Sales and marketing

    10,6268,38738,84029,156General and administrative

    6,9325,44624,52821,278Gain from legal settlement

    ———(243)Restructuring charge8212;8212;8212;747Total costs and operating expenses

    56,88753,239217,812193,993Income (loss) from operations

    1,839(4,035)(5,344)(23,366)Other income (expense), net

    (346)(223)(992)424Income (loss) before benefit (provision) for income taxes

    1,493(4,258)(6,336)(22,942)Benefit (provision) for income taxes

    (148)(24)419440Net income (loss)

    $   (4,282)$   (5,917)$  (22,502)Basic net income (loss) per share

    Diluted net income (loss) per share

    Shares used in computing basic net income (loss) per share

    60,41358,59659,71258,206Shares used in computing diluted net income (loss) per share

    63,37258,59659,71258,206CEPHEIDCONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS(in thousands)December 31,
    2010December 31,
    2009ASSETSCurrent assets:Cash and cash equivalents

    35,786Short-term investments

    —24,931Accounts receivable, net


    37,59838,015Prepaid expenses and other current assets

    4,1382,421Total current assets

    149,284124,167Property and equipment, net

    27,43824,021Other non-current assets

    607495Intangible assets


    18,59418,626Total assets

    LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable

    22,068Accrued compensation

    12,5948,869Accrued royalties

    7,99412,929Accrued other liabilities

    1,2881,800Current portion of deferred revenue

    8,2072,923Current portion of note payable

    1,679108Bank borrowing8212;14,618Total current liabilities

    53,71963,315Long-term portion of deferred revenue

    4,0572,279Note payable, less current portion

    4,991732Other liabilities

    4,1824,234Total liabilities

    66,94970,560Shareholders' equity:Common stock

    288,387273,052Additional paid-in capital

    72,73156,408Accumulated other comprehensive income

    726371Accumulated deficit

    (208,182)(202,265)Total shareholders' equity

    153,662127,566Total liabilities and shareholders' equity


    December 31,20102009Cash flows from operating activities:Net loss

    $ (5,917)$ (22,502)Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization

    9,3268,808Amortization of intangible assets

    6,9666,823Amortization of prepaid compensation expense

    —147Stock-based compensation related to employees and consulting services rendered

    16,61515,215Write-offs of intangible assets

    271—Unrealized gain on auction rate securities

    (1,714)(6,734)Unrealized loss on put option

    1,8446,143Deferred rent

    85(26)Changes in operating assets and liabilities:Accounts receivable


    124(4,937)Prepaid expenses and other current assets

    (1,426)2,059Other non-current assets

    (113)425Accounts payable and other current liabilities

    (5,112)10,753Accrued compensation

    3,726949Deferred revenue

    7,062615Net cash provided by operating activities

    27,34313,676Cash flows from investing activities:Capital expenditures

    (13,047)(8,575)Acquisition of leasehold improvements

    125—Payments for technology licenses

    (1,000)(1,500)Cost of acquisition, net

    (1,300)(148)Proceeds from sales and maturities of marketable securities and short-term investments

    24,800200Proceeds from the sale of fixed assets

    13820Transfer to unrestricted cash8212;1,500Net cash provided by (used in) investing activities

    9,716(8,503)Cash flows from financing activities:Net proceeds from the issuance of common shares and exercise of stock options and awards

    15,3346,061Proceeds from bank borrowing

    —20Proceeds from note payable

    6,448849Principal payments of bank borrowing

    (14,618)(40)Principal payments of notes payable

    (618)(9)Net cash provided by financing activities

    6,5466,881Effect of exchange rate change on cash

    147254Net increase in cash and cash equivalents

    43,75212,308Cash and cash equivalents at beginning of period

    35,78623,478Cash and cash equivalents at end of period

    $ 79,538$  35,786CEPHEIDRECONCILIATION OF GAAP TO NON-GAAP MEASURES (UNAUDITED)(in thousands, except per share data)Three Months EndedDecember 31,Year EndedDecember 31,2010200920102009Cost of product sales

    $  26,570$  27,837$ 105,135$  95,542  Stock compensation expense

    (687)(682)(2,522)(2,411)  Amortization of purchased intangible assets

    (394)(324)(1,422)(1,296)Non-GAAP measure of cost of product sales

    $  25,489$  26,831$ 101,191$  91,835Gross margin on product sales per GAAP

    53%42%49%42%Gross margin on product sales per non-GAAP

    55%44%51%44%Operating expenses

    $  29,224$  23,749$ 105,871$  89,747  Stock compensation expense

    (3,614)(3,502)(14,093)(12,679)  Amortization of purchased intangible assets

    (78)(83)(409)(332)Non-GAAP measure of operating expenses

    $  25,532$  20,164$   91,369$  76,736Income (loss) from operations

    ,839$  (4,035)$   (5,344)$ (23,366)  Restructuring charge

    ———747  Stock compensation expense

    4,3014,18416,61515,090  Amortization of purchased intangible assets

    4724071,8311,628Non-GAAP measure of income (loss) from operations

    556$   13,102$   (5,901)Net income (loss)

    ,345$  (4,282)$   (5,917)$ (22,502)  Restructuring charge

    ———747  Stock compensation expense

    4,3014,18416,61515,090  Amortization of purchased intangible assets

    4724071,8311,628Non-GAAP measure of net income (loss)

    309$   12,529$   (5,037)Basic net income (loss) per share

    (0.39)  Restructuring charge

    ———0.01  Stock compensation expense  Amortization of purchased intangible assets measure of net income (loss)

    (0.09)Diluted net income (loss) per share

    (0.39)  Restructuring charge

    ———0.01  Stock compensation expense  Amortization of purchased intangible assets measure of net income (loss)

    (0.09)Shares used in computing basic net income (loss) per share

    60,41358,59659,71258,206  Incremental shares from the assumed conversion of dilutive stock options

    4,3262,7583,8758212;Shares used in computing Non-GAAP diluted net income (loss) per share

    64,73961,35463,58758,206CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

    Jacquie RossCepheid Corporate Communications

    Cepheid Investor RelationsTel: (408) 400 8377

    Tel: (408) 400

    SOURCE Cepheid
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
    2. Cepheid Launches New GeneXpert(R) Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus
    3. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
    4. Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection
    5. Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized Moderate Complexity by FDA
    6. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
    7. Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System
    8. Cepheid Reports 2009 Third Quarter Results
    9. Cepheid to Webcast Upcoming Financial Presentations
    10. Cepheid Collaborates With Pharmaceutical Leader on Chronic Myelogenous Leukemia
    11. Cepheid to Webcast Upcoming Financial Presentation
    Post Your Comments:
    (Date:11/30/2015)... 2015 North America was ... grow at a CAGR of 7.6% from 2015 to 2020. ... 135.6 million in 2014, and is expected to grow at a ... to the new Market Research Report "North America Cardiac Output Monitoring ... (Hospitals, ambulatory care, others) - Analysis And Forecast To 2020", the ...
    (Date:11/30/2015)... --> --> ... by Product (Soft Tissue, All Tissue, Dental Welding Lasers), Application ... Geography - Global Forecast to 2020", published by MarketsandMarkets, is ... CAGR of 5.2% during the forecast period from 2015 to ... 62 Figures spread through 167 P ages and in-depth ...
    (Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
    Breaking Medicine Technology:
    (Date:11/30/2015)... , ... December 01, 2015 , ... ... Dale Jones as a 2015-2016 inductee into its VIP Woman of the ... NAPW is the nation’s leading networking organization exclusively for professional women, boasting 850,000 ...
    (Date:11/30/2015)... ... December 01, 2015 , ... Live Very Well is ... insurance plans on . The multi-carrier insurance exchange platform offers individual ... allowing consumers to compare, quote and match plans to meet their needs. ...
    (Date:11/30/2015)... ... 30, 2015 , ... Until now, the St. Louis Fetal Care Institute ... of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI above 34.9. ... to 24.9 is considered normal, 25 - 29.9 is overweight and above 30 is ...
    (Date:11/30/2015)... , ... November 30, 2015 , ... Stress, anxiety, illness, ... a parent worry about possible tumors? , Heather Spader, MD, a new pediatric neurosurgeon ... are common, some signs might point to tumors. , “Bad headaches that ...
    (Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a world leader in ... its ThermiRFR temperature controlled radiofrequency platform has received CE marking and may now ... uses temperature as a clinical endpoint. The technology has been available in ...
    Breaking Medicine News(10 mins):